AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Using AKT Inhibitors in mCRPC
Daniel George notes activity in CRPC but prefers using capivasertib earlier where dependence on AKT is greater.
Play episode from 01:01:34
Transcript
